メニュー
Request a Quote
お問い合わせ
JP
Literature - Publication Review

Improving engineered T cell efficacy for treating solid tumors through epigenetic modulation

engineered-t-cells-epigenetic-modulation-opera-ivis512x288

The high heterogeneity, lack of tumor-specific targets, and immunosuppressive tumor microenvironment of solid tumors are all significant hurdles for the development of T cell therapies.

Learn how researchers set out to engineer T cells with the objective of introducing small molecule epigenetic inhibitors to assess their impact on T cell cytotoxicity. The research team used the Opera® Phenix high-content screening system to quantify cytotoxicity and migration of the engineered T-cells. Non-invasive in vivo imaging using the IVIS® system was then performed in a mouse tumor model to evaluate efficacy of engineered T-cells on tumor burden.

This study demonstrates how epigenetic modulation may be a promising development in improving future cancer immunotherapy for solid tumors.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Improving engineered T cell efficacy for treating solid tumors through epigenetic modulation

Download Literature - Publication Review